Cai Tommaso, Cocci Andrea, Verze Paolo, Rizzo Michele, Palmieri Alessandro, Liguori Giovanni, Trombetta Carlo, Adembri Chiara, Carini Marco, Bartoletti Riccardo, Wagenlehner Florian M, Bonkat Gernot, Mirone Vincenzo, Bjerklund Johansen Truls E, Novelli Andrea
a Department of Urology , Santa Chiara Regional Hospital , Trento , Italy.
b Department of Urology , University of Florence , Florence , Italy.
J Chemother. 2018 Sep;30(5):290-295. doi: 10.1080/1120009X.2018.1500110.
We present the results of a multicenter retrospective study of 35 difficult-to-treat patients with urinary tract infections associated with indwelling urinary catheters (CAUTIs). All patients received oral administration of 3 g fosfomycin trometamol once a day for two days and then with a dose of 3 g every 48 h for two weeks. The most commonly isolated strains were: Escherichia coli (65.7%) and Enterococcus spp. (25.7%); prevalence of Extended-Spectrum Beta-Lactamase strains was 48.5%. Six patients (17.1%) had a clinical response after a single dose of fosfomycin trometamol, 12 (34.2%) after two doses and 13 (37.1%) patients had a clinical response after three or more doses. Four patients (11.6%) failed prolonged antibiotic treatment with fosfomycin trometamol. During the follow-up period, 30 out of 35 (85.7%) patients were without symptomatic infections. No significant side effects were reported. In conclusion, fosfomycin trometamol seems to be a valid treatment option in patients with CAUTIs.
我们展示了一项针对35例留置导尿管相关尿路感染（CAUTIs）的难治性患者的多中心回顾性研究结果。所有患者每天口服一次3克磷霉素氨丁三醇，持续两天，然后每48小时服用3克，持续两周。最常分离出的菌株为：大肠埃希菌（65.7%）和肠球菌属（25.7%）；超广谱β-内酰胺酶菌株的患病率为48.5%。6例患者（17.1%）在单次服用磷霉素氨丁三醇后有临床反应，12例（34.2%）在两次服药后有临床反应，13例（37.1%）患者在三次或更多次服药后有临床反应。4例患者（11.6%）接受磷霉素氨丁三醇长期抗生素治疗失败。在随访期间，35例患者中有30例（85.7%）无感染症状。未报告明显副作用。总之，磷霉素氨丁三醇似乎是CAUTIs患者的一种有效治疗选择。
